MY148470A - Indole derivatives as s1p1 receptor agonists - Google Patents

Indole derivatives as s1p1 receptor agonists

Info

Publication number
MY148470A
MY148470A MYPI20092612A MYPI20092612A MY148470A MY 148470 A MY148470 A MY 148470A MY PI20092612 A MYPI20092612 A MY PI20092612A MY PI20092612 A MYPI20092612 A MY PI20092612A MY 148470 A MY148470 A MY 148470A
Authority
MY
Malaysia
Prior art keywords
receptor agonists
indole derivatives
receptor
disorders
hydrogen
Prior art date
Application number
MYPI20092612A
Other languages
English (en)
Inventor
Ahmed Mohmood
Myatt James
Norton David
Ivers Dean Andrew
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY148470(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0625647A external-priority patent/GB0625647D0/en
Priority claimed from GB0707615A external-priority patent/GB0707615D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY148470A publication Critical patent/MY148470A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
MYPI20092612A 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists MY148470A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0625647A GB0625647D0 (en) 2006-12-21 2006-12-21 Compounds
GB0707615A GB0707615D0 (en) 2007-04-19 2007-04-19 Compounds

Publications (1)

Publication Number Publication Date
MY148470A true MY148470A (en) 2013-04-30

Family

ID=39283563

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI20092612A MY148470A (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists
MYPI2012004367A MY156822A (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2012004367A MY156822A (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists

Country Status (32)

Country Link
US (1) US8101775B2 (OSRAM)
EP (2) EP2206710B1 (OSRAM)
JP (1) JP5309034B2 (OSRAM)
KR (1) KR101495927B1 (OSRAM)
CN (1) CN103012390B (OSRAM)
AR (1) AR064452A1 (OSRAM)
AT (1) ATE509927T1 (OSRAM)
AU (1) AU2007336224B2 (OSRAM)
BR (1) BRPI0721127A2 (OSRAM)
CA (1) CA2673468C (OSRAM)
CL (1) CL2007003755A1 (OSRAM)
CR (2) CR10922A (OSRAM)
CY (2) CY1111702T1 (OSRAM)
DK (2) DK2206710T3 (OSRAM)
DO (1) DOP2009000133A (OSRAM)
EA (1) EA017406B1 (OSRAM)
ES (1) ES2389879T3 (OSRAM)
HR (2) HRP20110456T1 (OSRAM)
IL (1) IL199187A (OSRAM)
JO (1) JO2701B1 (OSRAM)
MA (1) MA30999B1 (OSRAM)
MX (1) MX2009006882A (OSRAM)
MY (2) MY148470A (OSRAM)
NO (1) NO20092385L (OSRAM)
NZ (1) NZ577387A (OSRAM)
PE (2) PE20081398A1 (OSRAM)
PL (2) PL2206710T3 (OSRAM)
PT (2) PT2091949E (OSRAM)
SG (1) SG177914A1 (OSRAM)
SI (2) SI2206710T1 (OSRAM)
TW (1) TWI393564B (OSRAM)
WO (1) WO2008074821A1 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2003132E (pt) 2006-04-03 2014-05-26 Astellas Pharma Inc Derivados de oxadiazole como agonistas dos s1p1
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
DE602008005285D1 (de) 2007-04-19 2011-04-14 Glaxo Group Ltd Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) -agonisten
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
PL2913326T3 (pl) 2008-05-14 2020-11-16 The Scripps Research Institute Nowe modulatory receptorów fosforanu sfingozyny
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
AR072184A1 (es) * 2008-06-20 2010-08-11 Glaxo Group Ltd Derivados de oxadiazol como agonistas del receptor s1p1
HRP20141152T1 (hr) * 2008-07-23 2015-01-16 Novartis Ag Modulatori receptora sfingozin-1-fosfata i njihova uporaba za lijeäśenje upale mišiä†a
KR20220084423A (ko) 2008-07-23 2022-06-21 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
BRPI0917923B1 (pt) 2008-08-27 2022-04-05 Arena Pharmaceuticals Inc Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição
CA2743397C (en) * 2008-12-18 2017-02-28 Mathilde Muzerelle Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
KR101721716B1 (ko) 2009-11-13 2017-04-10 레셉토스,엘엘씨 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법
WO2011072488A1 (en) * 2009-12-18 2011-06-23 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CA2789480A1 (en) * 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
US8835470B2 (en) 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
UA113507C2 (xx) 2011-02-07 2017-02-10 Модулятори s1p
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
EP3310760B8 (en) 2015-06-22 2022-10-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
RU2754845C2 (ru) * 2016-07-22 2021-09-08 Медшайн Дискавери Инк. Агонист s1p1 и его применение
WO2018064356A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
EP3582772A1 (en) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
KR102836433B1 (ko) 2018-09-06 2025-07-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물
KR20220093330A (ko) 2019-10-31 2022-07-05 이도르시아 파마슈티컬스 리미티드 Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
AU2020397746B2 (en) 2019-12-03 2024-02-01 Lg Chem, Ltd. Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient
EP4103549A1 (en) * 2020-02-11 2022-12-21 Syngenta Crop Protection AG Pesticidally active cyclic amine compounds
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de) 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
CN1788008A (zh) * 2003-05-15 2006-06-14 麦克公司 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
AU2004277947A1 (en) 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
US7659294B2 (en) 2004-10-22 2010-02-09 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
JP5024039B2 (ja) 2005-02-25 2012-09-12 小野薬品工業株式会社 インドール化合物およびその用途
DE602006003642D1 (en) 2005-03-23 2008-12-24 Actelion Pharmaceuticals Ltd Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten
TW200642683A (en) 2005-04-22 2006-12-16 Sankyo Co Heterocyclic compound
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
CN101291908A (zh) 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2007262009A (ja) * 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
PT2003132E (pt) * 2006-04-03 2014-05-26 Astellas Pharma Inc Derivados de oxadiazole como agonistas dos s1p1
MX2009002233A (es) 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
DE602008005285D1 (de) * 2007-04-19 2011-04-14 Glaxo Group Ltd Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) -agonisten

Also Published As

Publication number Publication date
AU2007336224A1 (en) 2008-06-26
CY1113131T1 (el) 2016-04-13
EP2206710A1 (en) 2010-07-14
DOP2009000133A (es) 2009-08-15
NZ577387A (en) 2012-01-12
PT2206710E (pt) 2012-09-10
PL2091949T3 (pl) 2011-10-31
ES2389879T3 (es) 2012-11-02
PT2091949E (pt) 2011-07-13
WO2008074821A1 (en) 2008-06-26
CN103012390A (zh) 2013-04-03
AR064452A1 (es) 2009-04-01
IL199187A0 (en) 2010-03-28
HRP20110456T1 (hr) 2011-07-31
MX2009006882A (es) 2009-07-03
CY1111702T1 (el) 2015-10-07
US20100113796A1 (en) 2010-05-06
KR101495927B1 (ko) 2015-02-25
PE20121076A1 (es) 2012-09-05
PL2206710T3 (pl) 2012-11-30
CN103012390B (zh) 2015-08-26
AU2007336224B2 (en) 2013-01-10
US8101775B2 (en) 2012-01-24
DK2206710T3 (da) 2012-08-27
TW200843736A (en) 2008-11-16
JO2701B1 (en) 2013-03-03
CR10922A (es) 2009-08-12
EA200970612A1 (ru) 2009-10-30
EP2091949B1 (en) 2011-05-18
SI2091949T1 (sl) 2011-08-31
MA30999B1 (fr) 2009-12-01
CL2007003755A1 (es) 2008-08-22
NO20092385L (no) 2009-08-24
MY156822A (en) 2016-03-31
EP2091949A1 (en) 2009-08-26
CA2673468C (en) 2015-06-02
CR20140316A (es) 2014-08-20
HK1140761A1 (en) 2010-10-22
HK1130255A1 (en) 2009-12-24
EA017406B1 (ru) 2012-12-28
CA2673468A1 (en) 2008-06-26
TWI393564B (zh) 2013-04-21
SI2206710T1 (sl) 2012-10-30
SG177914A1 (en) 2012-02-28
PE20081398A1 (es) 2008-11-19
BRPI0721127A2 (pt) 2014-03-11
EP2206710B1 (en) 2012-07-04
KR20090092290A (ko) 2009-08-31
DK2091949T3 (da) 2011-07-18
HRP20120685T1 (hr) 2012-09-30
IL199187A (en) 2015-04-30
ATE509927T1 (de) 2011-06-15
JP5309034B2 (ja) 2013-10-09
JP2010513397A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
MY148470A (en) Indole derivatives as s1p1 receptor agonists
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
JO2686B1 (en) Vehicles
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
MY148634A (en) Pyridazinone derivatives
MX2010012390A (es) Derivados de indazoles sustituidos con fenilo o piridinilo.
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
JO2645B1 (en) Vehicles
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
GEP20094727B (en) Oxyindole derivatives as 5ht4 receptor agonists
IN2012DN03042A (OSRAM)
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
MX2009010225A (es) Nuevos compuestos 707 y sus usos.
UA102508C2 (ru) Производные индола как агонисты рецептора s1p1
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
GB0524814D0 (en) Compounds